Delivery Order SPE2DB22D3016-SPE2DB25FAWV8
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Dexmethylphenidate ER 20 mg capsules (100-count units) with a ceiling value of $1,036.54. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be...
- The Defense Logistics Agency awarded a $1,419.38 delivery order to AmerisourceBergen Drug Corp for Dexmethylphenidate ER 15 mg capsules (100-count bottles) on July 28, 2025, with completion targeted for July 29, 2025. This non-set-aside, firm fixed-price contract represents a single delivery order issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Dexmethylphenidate ER 10 mg capsules (100-count) with a ceiling value of $1,202.32. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is scheduled for ultimate completion by August 7, 2025. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania facility, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $1,014.76 delivery order to AmerisourceBergen Drug Corp for Dexmethylphenidate ER 5 mg capsules (100-count units) on September 5, 2025, with an ultimate completion date of September 8, 2025. This competitive award, issued under a firm fixed-price contract type with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $1,143.20 to AmerisourceBergen Drug Corp for the supply of Dexmethylphenidate ER 25 mg capsules (100 count) on August 11, 2025, with completion scheduled for August 12, 2025. This competitive, non-set-aside delivery order utilizes firm fixed price terms and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,605.70 to AmerisourceBergen Drug Corp for the supply of Dexmethylphenidate ER 30 mg capsules (100 count). This competitively awarded contract, issued on September 3, 2025, with an ultimate completion date of September 4, 2025, represents a firm fixed-price delivery order with no set-aside designation. The pharmaceutical product will be performed and delivered from AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency has awarded a delivery order valued at $2,004.58 to AmerisourceBergen Drug Corp for the supply of Dexmethylphenidate ER 10 mg capsules (100-count package). This competitively awarded, firm fixed-price delivery order was issued on September 19, 2025, with an ultimate completion date of September 22, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its Corporate Office location. The order carries no set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,263.91 to AmerisourceBergen Drug Corp for the supply of Dexmethylphenidate ER 20 mg capsules (100 count) under a firm fixed price contract. The delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 2, 2025. AmerisourceBergen will perform the work from its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 8, 2025, for the supply of Dexmethylphenidate ER 10 mg capsules (100 count) with a ceiling value of $1,606.41. This is a firm fixed-price delivery order with no set-aside designation, executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion and running through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $12,865.02 delivery order to AmerisourceBergen Drug Corp for Dexmethylphenidate ER 15 mg capsules (100 count) with a completion date of May 29, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB25FAWV8Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,109.10 to AmerisourceBergen Drug Corp for Dexmethylphenidate ER 10 mg capsules (100 count) on May 20, 2025, with completion scheduled for May 21, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls within AmerisourceBergen's comprehensive pharmaceutical support vehicle that enables the company to supply medications, vaccines, and medical supplies to support military healthcare programs worldwide. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The underlying IDC represents a flexible contract mechanism supporting DLA's pharmaceutical supply chain operations and complements the agency's planned Pharmaceutical Prime Vendor Global Program Generation V contracts, which are expected to make multiple awards across separate regions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 5/20/25 |